We are live on ! Find out more
GEVA

SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA

Delisted

GEVA was delisted on the 22nd of June, 2015.

Back to rankings

95 hedge funds and large institutions have $1.92B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2013 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 28 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,848% more call options, than puts

Call options by funds: $10.8M | Put options by funds: $557K

76% more capital invested

Capital invested by funds: $1.09B → $1.92B (+$825M)

70% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 10

54% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 28

7% more funds holding

Funds holding: 89 → 95 (+6)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
95
Holders Change
+6
Holders Change %
+6.74%
% of All Funds
3.08%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
17
Increased
43
Reduced
28
Closed
10
Calls
$10.8M
Puts
$557K
Net Calls
+$10.3M
Net Calls Change
+$10.9M

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$51.7M
2
CWAM
Columbia Wanger Asset Management
Illinois
+$36.4M
3
BB
BB Biotech
Switzerland
+$32.5M
4
SAM
Sectoral Asset Management
Quebec, Canada
+$23.2M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$18.6M

Top Sellers

Rank Fund Capital Flow
1
TI
Turner Investments
Pennsylvania
-$8.81M
2
BA
BlackRock Advisors
Delaware
-$8.25M
3
Wells Fargo
Wells Fargo
California
-$8.16M
4
DCM
Driehaus Capital Management
Illinois
-$6.07M
5
Millennium Management
Millennium Management
New York
-$5.34M
Name Holding Trade Value Shares
Change 		Change in
Stake
MOACM
51
Mutual of America Capital Management
New York
$1.15M +$22.5K +457 +3%
American Century Companies
52
American Century Companies
Missouri
$1.15M +$54.6K +1,110 +7%
SFM
53
Soros Fund Management
New York
$1.12M +$871K +17,700 New
Morgan Stanley
54
Morgan Stanley
New York
$1.03M -$383K -7,784 -32%
RhumbLine Advisers
55
RhumbLine Advisers
Massachusetts
$978K -$2.12K -43 -0.3%
DekaBank Deutsche Girozentrale
56
DekaBank Deutsche Girozentrale
Germany
$964K +$59.1K +1,200 +9%
Swiss National Bank
57
Swiss National Bank
Switzerland
$956K +$64K +1,300 +9%
MLICM
58
Metropolitan Life Insurance Company (MetLife)
New York
$877K – – –
NFA
59
Nationwide Fund Advisors
Ohio
$858K -$889K -18,052 -57%
Susquehanna International Group
60
Susquehanna International Group
Pennsylvania
$855K -$89.3K -1,814 -12%
AIG
61
American International Group
New York
$726K +$182K +3,699 +48%
State Board of Administration of Florida Retirement System
62
State Board of Administration of Florida Retirement System
Florida
$713K – – –
VOYA Investment Management
63
VOYA Investment Management
Georgia
$669K – – –
CII
64
CR Intrinsic Investors
Connecticut
$633K -$5.32M -108,161 -92%
Barclays
65
Barclays
United Kingdom
$617K +$370K +7,522 +331%
JP Morgan Chase
66
JP Morgan Chase
New York
$611K -$412K -8,361 -46%
MAA
67
Managed Account Advisors
New Jersey
$607K -$415K -8,434 -47%
TC
68
TFS Capital
Pennsylvania
$589K +$457K +9,284 New
STIA
69
Stone Toro Investment Advisers
New Jersey
$564K +$438K +8,900 New
CS
70
Credit Suisse
Switzerland
$495K -$1.07M -21,654 -74%
Group One Trading
71
Group One Trading
Illinois
$468K +$364K +7,400 New
DL
72
Delta Lloyd
Netherlands
$465K -$123K -2,500 -25%
Bank of Montreal
73
Bank of Montreal
Ontario, Canada
$392K +$246 +5 +0.1%
GH
74
GAM Holding
Switzerland
$380K +$295K +6,000 New
Citigroup
75
Citigroup
New York
$341K +$238K +4,838 +872%
1 2
3
4 5

GEVA Hedge Fund Activity: Q3 2013 in Review

95 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q3 2013, worth a combined $1.92B — up 76% from $1.09B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new GEVA positions and 10 closed out — a net gain of 7 holders — while 43 added to existing stakes and 28 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $51.7M. The largest seller was Turner Investments, exiting entirely with an estimated $8.81M sold.

  • 95 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q3 2013, up from 89 in Q2 2013.
  • Funds reported $1.92B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q3 2013, up 76% quarter-over-quarter.
  • 17 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q3 2013 and 10 closed out, a net change of +7 holders.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) buyer in Q3 2013 was Baker Bros. Advisors, an estimated $51.7M added.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q3 2013 was Turner Investments, an estimated $8.81M sold.

Based on aggregated 13F filings for Q3 2013.